MRUS Merus NV

Price (delayed)

$57.26

Market cap

$3.36B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.77

Enterprise value

$3.19B

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed ...

Highlights
Merus's equity has soared by 61% YoY
The EPS has grown by 17% YoY and by 8% from the previous quarter
Merus's quick ratio has surged by 54% YoY but it has decreased by 2.1% QoQ
The revenue has declined by 13% since the previous quarter and by 12% year-on-year
Merus's gross profit has decreased by 13% QoQ and by 12% YoY

Key stats

What are the main financial stats of MRUS
Market
Shares outstanding
58.69M
Market cap
$3.36B
Enterprise value
$3.19B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.48
Price to sales (P/S)
86.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
83.31
Earnings
Revenue
$38.34M
EBIT
-$159.42M
EBITDA
-$156.86M
Free cash flow
-$150.28M
Per share
EPS
-$2.77
Free cash flow per share
-$2.59
Book value per share
$6.04
Revenue per share
$0.66
TBVPS
$8.55
Balance sheet
Total assets
$498.08M
Total liabilities
$148.64M
Debt
$11.53M
Equity
$349.45M
Working capital
$331.77M
Liquidity
Debt to equity
0.03
Current ratio
5.23
Quick ratio
5.05
Net debt/EBITDA
1.06
Margins
EBITDA margin
-409.2%
Gross margin
100%
Net margin
-390.4%
Operating margin
-434.6%
Efficiency
Return on assets
-33.1%
Return on equity
-44.1%
Return on invested capital
-75.2%
Return on capital employed
-38%
Return on sales
-415.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRUS stock price

How has the Merus stock price performed over time
Intraday
2.54%
1 week
7.35%
1 month
1.06%
1 year
117.39%
YTD
108.22%
QTD
-3.23%

Financial performance

How have Merus's revenue and profit performed over time
Revenue
$38.34M
Gross profit
$38.34M
Operating income
-$166.6M
Net income
-$149.65M
Gross margin
100%
Net margin
-390.4%
The operating margin has contracted by 22% from the previous quarter and by 11% YoY
The revenue has declined by 13% since the previous quarter and by 12% year-on-year
Merus's gross profit has decreased by 13% QoQ and by 12% YoY
MRUS's net margin is down by 12% year-on-year and by 11% since the previous quarter

Growth

What is Merus's growth rate over time

Valuation

What is Merus stock price valuation
P/E
N/A
P/B
9.48
P/S
86.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
83.31
The EPS has grown by 17% YoY and by 8% from the previous quarter
The P/B is 137% more than the 5-year quarterly average of 4.0 and 93% more than the last 4 quarters average of 4.9
Merus's equity has soared by 61% YoY
The P/S is 118% higher than the last 4 quarters average of 39.8
The revenue has declined by 13% since the previous quarter and by 12% year-on-year

Efficiency

How efficient is Merus business performance
The ROE has grown by 21% YoY and by 13% from the previous quarter
The ROS has contracted by 17% YoY and by 10% from the previous quarter
The ROIC has grown by 16% YoY and by 13% from the previous quarter
The ROA is up by 14% year-on-year and by 12% since the previous quarter

Dividends

What is MRUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRUS.

Financial health

How did Merus financials performed over time
Merus's quick ratio has surged by 54% YoY but it has decreased by 2.1% QoQ
The current ratio has surged by 52% year-on-year but it has declined by 2.1% since the previous quarter
MRUS's debt is 97% smaller than its equity
Merus's equity has soared by 61% YoY
MRUS's debt to equity has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.